Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask (EpiCapno)
This study is not yet open for participant recruitment.
Verified September 2012 by University of Aarhus
Sponsor:
University of Aarhus
Collaborator:
Aarhus University Hospital
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01657084
First received: August 1, 2012
Last updated: September 12, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
By enabling a partial rebreathing of expired gas, a moderate respiratory acidosis is induced, without causing hypoxia in the patient.
Based on the scientific literature on the subject, the study hypothesis is that the fall in body pH will be able to stop and/or prevent epileptic brain activity.
| Condition | Intervention |
|---|---|
|
Epilepsy |
Device: CDA Mask Device: Dummy mask |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask |
Resource links provided by NLM:
Genetics Home Reference related topics:
pyridoxal 5'-phosphate-dependent epilepsy
U.S. FDA Resources
Further study details as provided by University of Aarhus:
Primary Outcome Measures:
- Length of epileptic seizure (subgroup 1) [ Time Frame: Duration of mask treatment during acute seizures: approx. 3 minutes from start of mask treatment until end of seizure ] [ Designated as safety issue: No ]Length of epileptic seizure with treatment mask vs. dummy mask
- Frequency of epileptic paroxysms (subgroup 2) [ Time Frame: Duration of mask treatment: 45 minutes during which patient is monitored with EEG ] [ Designated as safety issue: No ]Frequency of epileptic paroxysms as measured by EEG, treatment mask vs. dummy mask
Secondary Outcome Measures:
- Oxygen saturation during mask treatment [ Time Frame: Duration of mask treatment ] [ Designated as safety issue: Yes ]Measures oxygen saturation using a pulse oximeter during mask treatment
| Estimated Enrollment: | 20 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tonic-Clonic Seizures
Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
|
Device: CDA Mask
The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
Device: Dummy mask
The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
|
|
Experimental: Generalized Paroxysms
Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
|
Device: CDA Mask
The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
Device: Dummy mask
The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Epilepsy
- 18-80 years
Exclusion Criteria:
-
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01657084
Contacts
| Contact: Jakob Christensen, MD, PhD | +45 60865899 | JAKOB@FARM.AU.DK |
| Contact: Troels Johansen, M.Sc.Eng. | + 40977313 | troels.johansen@ki.au.dk |
Locations
| Denmark | |
| Aarhus University Hospital | Not yet recruiting |
| Aarhus, Denmark, 8000 | |
Sponsors and Collaborators
University of Aarhus
Aarhus University Hospital
Investigators
| Principal Investigator: | Jakob Christensen, M.D., Ph.d. | Aarhus University Hospital |
More Information
No publications provided
| Responsible Party: | University of Aarhus |
| ClinicalTrials.gov Identifier: | NCT01657084 History of Changes |
| Other Study ID Numbers: | 2012051485 |
| Study First Received: | August 1, 2012 |
| Last Updated: | September 12, 2012 |
| Health Authority: | Denmark: Danish Health and Medicines Authority Denmark: Danish Dataprotection Agency |
Additional relevant MeSH terms:
|
Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013